In an analogous study by Mozzanica et al. six patients with nodular (2) or superficial (4) basal cell carcinomas were treated with intralesional injections of IFN-α-2b (1.5 million IU per injection) three times a week for three weeks. Here, IFNA2 is linked to basal cell carcinoma.